Cancer Research Cell Death Mechanisms and Cancer Therapy  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rödel, F.
Right arrow Articles by Rödel, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rödel, F.
Right arrow Articles by Rödel, C.
[Cancer Research 65, 4881-4887, June 1, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Survivin as a Radioresistance Factor, and Prognostic and Therapeutic Target for Radiotherapy in Rectal Cancer

Franz Rödel1, Jörg Hoffmann1, Luitpold Distel1, Martin Herrmann2, Timmo Noisternig1, Thomas Papadopoulos3, Rolf Sauer1 and Claus Rödel1

1 Department of Radiation Oncology, Institutes of 2 Clinical Immunology, and 3 Pathology, University of Erlangen-Nuremberg, Erlangen, Germany

Requests for reprints: Franz Rödel, Department of Radiation Therapy, Universitätsstr. 27, 91054 Erlangen, Germany. Phone: 49-9131-853-3405; Fax: 49-9131-853-9335; E-mail: franz.roedel{at}strahlen.med.uni-erlangen.de.

Apoptosis levels have been shown to predict tumor response to preoperative radiochemotherapy in rectal cancer. Recently, the prominent role of survivin, a structurally unique member of the inhibitor of apoptosis protein family, has been shown in colorectal cancer tumorigenesis and prognosis. In this study, we investigated whether survivin plays a direct role in mediating radiation resistance. We used short interfering RNA molecules to decrease survivin in radioresistant SW480 and intermediately radioresistant HCT-15 colorectal cancer cells. This resulted in a significant decrease of survivin mRNA and protein expression with a maximum at 24 to 48 hours after transfection. If irradiated during this sensitive period, an increased percentage of apoptotic cells and an increased caspase 3/7 activity in parallel with a decreased cell viability and a reduced clonogenic survival was shown. These effects were more pronounced in the radioresistant SW480 cell line with a radiation-induced cytotoxicity enhancement factor at 10% and 50% survival of 1.8 to 2.2 for SW480 and 1.5 to 1.7 for HCT-15, respectively. Furthermore, transfection with survivin short interfering RNA increased levels of G2-M arrest and levels of DNA double-strand breaks in irradiated cells. These observations indicate that cell cycle and DNA repair mechanisms may be associated with apoptosis induction in tumor cells that are otherwise resistant to killing by radiation. In a translational study of 59 patients with rectal cancer treated with a combination of radiotherapy and chemotherapy, increased survivin expression was inversely related to the levels of apoptosis, and was also associated with a significantly higher risk of a local tumor recurrence.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. Konduri, J. Colon, C. H. Baker, S. Safe, J. L. Abbruzzese, A. Abudayyeh, Md. R. Basha, and M. Abdelrahim
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression
Mol. Cancer Ther., March 1, 2009; 8(3): 533 - 542.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
G. JIANG, B. REN, L. XU, S. SONG, C. ZHU, and F. YE
Survivin May Enhance DNA Double-strand Break Repair Capability by Up-regulating Ku70 in Human KB Cells
Anticancer Res, January 1, 2009; 29(1): 223 - 228.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Iwasa, I. Okamoto, M. Suzuki, T. Nakahara, K. Yamanaka, E. Hatashita, Y. Yamada, M. Fukuoka, K. Ono, and K. Nakagawa
Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines
Clin. Cancer Res., October 15, 2008; 14(20): 6496 - 6504.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. Kunnumakkara, P. Diagaradjane, S. Guha, A. Deorukhkar, S. Shentu, B. B. Aggarwal, and S. Krishnan
Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to {gamma}-Radiation by Targeting Nuclear Factor-{kappa}B-Regulated Gene Products
Clin. Cancer Res., April 1, 2008; 14(7): 2128 - 2136.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S.-K. Seo, H.-O. Jin, H.-C. Lee, S.-H. Woo, E.-S. Kim, D.-H. Yoo, S.-J. Lee, S. An, C.-H. Rhee, S.-I. Hong, et al.
Combined Effects of Sulindac and Suberoylanilide Hydroxamic Acid on Apoptosis Induction in Human Lung Cancer Cells
Mol. Pharmacol., March 1, 2008; 73(3): 1005 - 1012.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
P. Lechler, X. Wu, W. Bernhardt, V. Campean, S. Gastiger, T. Hackenbeck, B. Klanke, A. Weidemann, C. Warnecke, K. Amann, et al.
The Tumor Gene Survivin Is Highly Expressed in Adult Renal Tubular Cells: Implications for a Pathophysiological Role in the Kidney
Am. J. Pathol., November 1, 2007; 171(5): 1483 - 1498.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. de Heer, E. C. de Bruin, E. Klein-Kranenbarg, R. I.J.M. Aalbers, C. A.M. Marijnen, H. Putter, H. J. de Bont, J. F. Nagelkerke, J. H. J.M. van Krieken, H. W. Verspaget, et al.
Caspase-3 Activity Predicts Local Recurrence in Rectal Cancer
Clin. Cancer Res., October 1, 2007; 13(19): 5810 - 5815.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Pennati, M. Folini, and N. Zaffaroni
Targeting survivin in cancer therapy: fulfilled promises and open questions
Carcinogenesis, June 1, 2007; 28(6): 1133 - 1139.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
M. S. Chen, W. A. Woodward, F. Behbod, S. Peddibhotla, M. P. Alfaro, T. A. Buchholz, and J. M. Rosen
Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line
J. Cell Sci., February 1, 2007; 120(3): 468 - 477.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. K. Knauer, O. H. Kramer, T. Knosel, K. Engels, F. Rodel, A. F. Kovacs, W. Dietmaier, L. Klein-Hitpass, N. Habtemichael, A. Schweitzer, et al.
Nuclear export is essential for the tumor-promoting activity of survivin
FASEB J, January 1, 2007; 21(1): 207 - 216.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Zhu, L. Gu, H. W. Findley, C. Chen, J.-T. Dong, L. Yang, and M. Zhou
KLF5 Interacts with p53 in Regulating Survivin Expression in Acute Lymphoblastic Leukemia
J. Biol. Chem., May 26, 2006; 281(21): 14711 - 14718.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Tirro, M. L. Consoli, M. Massimino, L. Manzella, F. Frasca, L. Sciacca, L. Vicari, G. Stassi, L. Messina, A. Messina, et al.
Altered Expression of c-IAP1, Survivin, and Smac Contributes to Chemotherapy Resistance in Thyroid Cancer Cells.
Cancer Res., April 15, 2006; 66(8): 4263 - 4272.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Lotem, D. Netanely, E. Domany, and L. Sachs
Human cancers overexpress genes that are specific to a variety of normal human tissues
PNAS, December 20, 2005; 102(51): 18556 - 18561.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Rodel, P. Martus, T. Papadoupolos, L. Fuzesi, M. Klimpfinger, R. Fietkau, T. Liersch, W. Hohenberger, R. Raab, R. Sauer, et al.
Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer
J. Clin. Oncol., December 1, 2005; 23(34): 8688 - 8696.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.